CRITICAL PATH INSTITUTE (C-PATH) IMAGE: THE T1D CONSORTIUM IS WORKING TO QUALIFY ISLET AUTOIMMUNITY ANTIBODIES AS PROGNOSTIC BIOMARKERS TO BE USED IN THE DEVELOPMENT OF THERAPIES FOR THE TREATMENT, AND ULTIMATELY THE PREVENTION, OF TYPE 1 DIABETES. CREDIT: COURTESY OF C-PATH TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today...
